All tracked trials

Phase 2 and Phase 3 cancer trials run by companies on the Nasdaq or New York Stock Exchange.

1,669 trials · most recently edited first

DTILPrecision Biologics, Inc
0Calm
Study of NEO-201 in Solid Tumors Expansion Cohorts
Running, no new patientsPhase 1/2121 patientsMain results: Jun 17, 2026
AAPGAscentage Pharma Group Inc.
0Calm
Global Trial in APG2575 for Patients With CLL/SLL
Signing up patientsPhase 3400 patientsMain results: Dec 31, 2026
GSKGlaxoSmithKline
0Calm
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer
FinishedPhase 3666 patientsMain results: Feb 26, 2025
BMYBristol-Myers Squibb
10Calm
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
FinishedPhase 2468 patientsMain results: Jan 11, 2024
CGEMCullinan Therapeutics Inc.
10Calm
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
Running, no new patientsPhase 1/2284 patientsMain results: Oct 13, 2025
BMYBristol-Myers Squibb
10Calm
A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer
FinishedPhase 2135 patientsMain results: May 22, 2025
IPHAInnate Pharma
0Calm
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
Signing up patientsPhase 270 patientsMain results: Jun 2027
CRDFCardiff Oncology
0Calm
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
Running, no new patientsPhase 2110 patientsMain results: Nov 2026
COGTCogent Biosciences, Inc.
10Calm
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Signing up patientsPhase 3482 patientsMain results: Sep 30, 2025
TAKTakeda
5Calm
A Study of TAK-853 in Adult Participants With Folate Receptor Alpha-Positive Advanced Ovarian Cancer And Other Solid Tumors
Running, no new patientsPhase 1/228 patientsMain results: Apr 16, 2025
GSKGlaxoSmithKline
0Calm
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM
Running, no new patientsPhase 1/220 patientsMain results: Apr 17, 2025
BMYCelgene
10Calm
Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting
FinishedPhase 2186 patientsMain results: Apr 30, 2025
IOVAIovance Biotherapeutics, Inc.
0Calm
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Signing up patientsPhase 1/242 patientsMain results: Jun 2032
RCUSArcus Biosciences, Inc.
10Calm
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer
FinishedPhase 2151 patientsMain results: Jul 9, 2025
BNTXBioNTech SE
0Calm
A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
Signing up patientsPhase 1/2375 patientsMain results: Nov 2027
TAKTakeda
5Calm
A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
Running, no new patientsPhase 356 patientsMain results: May 30, 2025
EIKNEikon Therapeutics
0Calm
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
Signing up patientsPhase 1/2156 patientsMain results: Jun 1, 2027
MRKArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
5Calm
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
Running, no new patientsPhase 1/2190 patientsMain results: Sep 17, 2027
TAKTakeda
5Calm
A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)
Running, no new patientsPhase 252 patientsMain results: Apr 27, 2025
AZNAstraZeneca
0Calm
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
Running, no new patientsPhase 3185 patientsMain results: Apr 6, 2027
GSKGlaxoSmithKline
0Calm
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
Running, no new patientsPhase 3302 patientsMain results: Jan 29, 2024
CRISCuris, Inc.
0Calm
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
Signing up patientsPhase 2108 patientsMain results: Nov 2027
GSKGlaxoSmithKline
0Calm
All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
Running, no new patientsPhase 321 patientsMain results: May 27, 2024
IOVAIovance Biotherapeutics, Inc.
0Calm
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Signing up patientsPhase 1/253 patientsMain results: Sep 2027
AGENAgenus Inc.
0Calm
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
FinishedPhase 281 patientsMain results: Jan 5, 2026